<DOC>
	<DOCNO>NCT00000880</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness low dos cyclosporine ( CsA ) patient early HIV infection evaluate effect immune system . Activation T cell ( cell immune system ) lead HIV replication . Inhibition immune activation therefore potentially important area therapy patient early HIV infection . CsA capable decrease T cell activation , turn may decrease HIV replication .</brief_summary>
	<brief_title>A Study Test Effect Cyclosporine Immune System Patients With Early HIV Disease</brief_title>
	<detailed_description>There increase data potential inhibition immune activation primary therapy HIV infection . The rationale CsA therapy decrease T cell activation patient early HIV infection . Activation T cell lead translation transcription provirus , release viral progeny , ultimately cell death . T cell activation also lead increase cell death via apoptosis . CsA capable inhibit event thus may lead decreased CD4 cell turnover . This study 2 arm 15 patient . Patients Arm I receive placebo . Patients Arm II receive CsA . Each arm divide 2 stratum . Stratum 1 patient allow receive antiretroviral therapy . Stratum 2 patient must receive 1 follow 4 stable nucleoside analogue combination : 1 . Zidovudine ( ZDV ) plus lamivudine ( 3TC ) 2 . ZDV plus didanosine ( ddI ) 3 . Stavudine ( d4T ) plus 3TC 4. d4T plus ddI .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVpositive . Have CD4 count great equal 500/mm3 . Have plasma HIV RNA level great 600 copies/ml . Are 18 year age . Agree practice abstinence use barrier method birth control study . Exclusion Criteria You eligible study : Have history AIDSdefining illness , autoimmune disease , hypertension . Have renal disease . Have active infection HIV . Have use certain antiretroviral medication . Are pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>T-Lymphocytes</keyword>
	<keyword>Lymphocyte Transformation</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Immunosuppressive Agents</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>